Corpus overview


Overview

MeSH Disease

Human Phenotype

There are no HP terms in the subcorpus


Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome MESHD SARS-CoV-2

    Authors: Sreejith Rajasekharan; Rafaela Milan Bonotto; Yvette Kazungu; Lais Nascimento Alves; Monica Poggianella; Pamela Martinez Orellana; Natasa Skoko; Sulena Polez; Alessandro Marcello

    doi:10.1101/2020.05.18.101691 Date: 2020-05-18 Source: bioRxiv

    Repurposing clinically available drugs to treat the new coronavirus disease MESHD COVID-19 is an urgent need in these early stages of the SARS-CoV-2 pandemic, when very few treatment options are available. The iminosugar Miglustat is a well-characterized drug for the treatment of rare genetic lysosome storage diseases such as Gaucher MESHD and Niemann-Pick type C, and has also been described to be active against a variety of enveloped viruses. The activity of Miglustat is here demonstrated for SARS-CoV-2 at concentrations achievable in the plasma SERO by current clinical regimens without cytotoxicity. The drug acts at the post-entry level and leads to a marked decrease of viral proteins and release of infectious virus. The mechanism resides in the inhibitory activity towards -glucosidases that are involved in early stages of glycoprotein N-linked oligosaccharide processing in the endoplasmic reticulum, leading to a marked decrease of the viral Spike protein. The wealth of available data on the clinical use of Miglustat for the treatment of lysosomal storage disorders and the antiviral properties against SARS-CoV-2 make it an ideal candidate for drug repurposing.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.